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Abstract Several reports indicate that some GKq-coupled re-
ceptors antagonize the activation of phosphatidylinositol (PI)
3-kinase by receptor tyrosine kinases. We used Rat-1 ¢broblasts
expressing the K1A adrenergic receptor to study how this GKq-
coupled receptor inhibits platelet-derived growth factor (PDGF)
activation of PI 3-kinase. Phenylephrine (PE) stimulation of the
K1A adrenergic receptor inhibited PDGF-induced binding of PI
3-kinase to the PDGF receptor (PDGFR) and phosphorylation
of the PDGFR at Tyr751, which forms a docking site for PI
3-kinase. By contrast, activation of phospholipase CQ by PDGF
and phosphorylation of the PDGFR at Tyr716 and Tyr771 were
not inhibited by PE. The protein tyrosine phosphatase SHP-2,
which dephosphorylates Tyr751 on the PDGFR, was more ac-
tive in cells treated with PDGF plus PE than in cells treated
with either agent alone. PDGF-induced PI 3-kinase signaling
was also inhibited by treatment of cells with Pasteurella multo-
cida toxin to activate GKq. These results suggest that the K1A
adrenergic receptor, and perhaps other GKq-coupled receptors,
uses tyrosine dephosphorylation to block PI 3-kinase activation
by PDGF.
4 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Phosphatidylinositol (PI) 3-kinase mediates many of the
cellular actions of receptor tyrosine kinases [1]. Class IA PI
3-kinases are heterodimers between a p110 catalytic subunit
and a p85 or p55 regulatory subunit. The p85 subunit con-
tains two Src homology (SH) 2 domains that bind to speci¢c
phosphotyrosine motifs on receptor tyrosine kinases or their
substrates. For example, phospho-Tyr740 and phospho-
Tyr751 on the platelet-derived growth factor (PDGF) L re-
ceptor (PDGFRL) form a high-a⁄nity binding site that re-
cruits the p110/p85 heterodimer to the activated receptor [2].
This interaction leads to translocation of p110 to the mem-
brane and enhances its catalytic activity.
The serine/threonine protein kinase Akt is a major down-
stream e¡ector of PI 3-kinase [3]. Phosphoinositides generated
by PI 3-kinase bind to the pleckstrin homology domain of
Akt, inducing a conformational change that allows Akt to
be phosphorylated and activated. Substrates of Akt include
glycogen synthase kinase 3, whose phosphorylation and inac-
tivation is thought to contribute to insulin-stimulated glyco-
gen synthesis, and BAD, which loses its apoptotic function
upon phosphorylation by Akt [3]. Negative regulation of PI
3-kinase/Akt signaling can therefore have profound e¡ects on
glucose metabolism and cell survival.
We recently reported that stimulation of the K1A adrenergic
receptor, a serpentine receptor that signals through heterotri-
meric G proteins, inhibits PDGF activation of PI 3-kinase
and Akt in Rat-1 ¢broblasts [4]. In this study, we investigated
mechanisms by which the K1A adrenergic receptor might me-
diate this response. We present evidence that the K1A adren-
ergic receptor attenuates PDGF-dependent tyrosine phos-
phorylation of the PDGFR and recruitment of PI 3-kinase
to the activated receptor.
2. Materials and methods
2.1. Materials
Human recombinant PDGF A/B and phenylephrine (PE) were pur-
chased from Sigma. [Q-32P]ATP (3000 Ci/mmol) was from Perkin El-
mer Life Sciences. PI was purchased from Avanti Polar Lipids. PY20
phosphotyrosine antibody was from Transduction Laboratories. Rab-
bit polyclonal antibodies against the PDGFRL, phospholipase C
(PLC)Q1, SHP-2, and Akt (H-136) were from Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA. p85K monoclonal antibody and phospho-
Tyr716 PDGFRL antibody were from Upstate Biotechnology, Lake
Placid, NY, USA. Phospho-Ser473 Akt antibody was from Cell Sig-
naling Technology, and Pasteurella multocida toxin (PMT) was from
Calbiochem, San Diego, CA, USA. Rabbit antibodies to phospho-
Tyr771 PDGFRL were raised using the peptide KYADIESSN(pY)-
MAPYDK as an immunogen and were a⁄nity-puri¢ed (Alpha Diag-
nostic International, San Antonio, TX, USA).
2.2. Cell culture and lysate preparation
Rat-1 ¢broblasts stably expressing the human K1A adrenergic recep-
tor [5] were maintained in Dulbecco’s modi¢ed Eagle’s medium (Me-
diatech) with antibiotics and 10% fetal bovine serum (Sigma). The
cells were incubated overnight in serum-free medium before agonist
treatments. After treatment, cells were rinsed with ice-cold phosphate-
bu¡ered saline and scraped into lysis bu¡er (50 mM Tris, pH 7.5, 120
mM NaCl, 1% Triton X-100, 1 mM EDTA, 50 mM NaF, 40 mM
2-glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM benzami-
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dine, 0.5 mM phenylmethylsulfonyl £uoride, and 10 Wg/ml aprotinin
and leupeptin) on ice.
Homogenates were centrifuged at 15 000Ug for 15 min at 4‡C, and
protein concentrations were determined using a Bradford assay (Bio-
Rad).
2.3. Immunoprecipitation and Western blotting
Cell lysates containing equal amounts of protein were incubated
with the appropriate antibody for 2 h or overnight at 4‡C, and then
with 12.5 Wl of protein A or G agarose (Sigma) for 1 h. The beads
were either washed three times with lysis bu¡er and used for immu-
noblotting, or they were washed three times with lysis bu¡er and once
with the appropriate kinase assay bu¡er prior to performing kinase
assays. Immunoprecipitates or equal amounts of cell lysate protein
were subjected to SDS^polyacrylamide gel electrophoresis followed
by electrophoretic transfer onto nitrocellulose or polyvinylidene di-
£uoride membranes. Signals were visualized using horseradish peroxi-
dase-linked secondary antibodies (Amersham Pharmacia Biotechnol-
ogy) and a chemiluminescence kit (Perkin Elmer Life Sciences). Blots
were stripped as described earlier [4].
2.4. PI 3-kinase assay
PI 3-kinase activity was assayed following methods described pre-
viously [4].
2.5. SHP-2 assay
32P-labeled myelin basic protein was prepared using the Protein
Tyrosine Phosphatase Assay System kit from New England Biolabs.
Rat-1 cells in 10 cm dishes were serum-starved overnight after reach-
ing approximately 80% con£uence. After the treatments described in
the text, the cells were washed with cold phosphate-bu¡ered saline
and scraped into 1 ml of extraction bu¡er (50 mM Na2HPO4, 120
mM NaCl, 1% Triton X-100, 20 mM p-nitrophenyl phosphate, 2 mM
EDTA, 1 mM dithiothreitol, 20 mM NaF, 0.2 mM phenylmethylsul-
fonyl £uoride, 5 Wg/ml leupeptin, 1 Wg/ml pepstatin, 1.7 Wg/ml apro-
tinin, and 1 mM benzamidine, pH 7.0). After centrifuging for 10 min
at 15 000Ug at 4‡C, equal amounts of cell lysate protein were incu-
bated with 1 Wg of SHP-2 antibody for 3 h on ice, and then with 12.5
Wl of protein A agarose for 1 h. The beads were washed three times
with extraction bu¡er and once with phosphatase assay bu¡er (New
England Biolabs) containing only 1 mM dithiothreitol. Phosphatase
assays (50 Wl) contained 5 Wl of 32P-labeled myelin basic protein and
1 mg/ml bovine serum albumin in assay bu¡er. After 30 min at 37‡C,
the assays were stopped and the 32Pi released was determined accord-
ing to the kit instructions.
2.6. PDGFR autophosphorylation assay
Washed PDGFRL immunoprecipitates were suspended in 25 Wl of
kinase assay bu¡er (50 mM Tris, pH 7.5, 10 mM MgCl2, 1 mM
dithiothreitol, 1 mM benzamidine, and 0.5 mM phenylmethylsulfonyl
£uoride) containing 10 WCi of [Q-32P]ATP. After incubation for 30 min
at 37‡C, the reactions were terminated by heating with SDS sample
bu¡er and the samples were subjected to SDS^polyacrylamide gel
electrophoresis.
3. Results
3.1. PE inhibits PDGF-induced PI 3-kinase activation
We showed earlier that PE stimulation of the K1A adrener-
gic receptor in Rat-1 cells inhibited PDGF-induced activation
of PI 3-kinase, as measured in phosphotyrosine immunopre-
cipitates [4]. To further examine the e¡ect of the K1A adren-
ergic receptor on PI 3-kinase activation, we assayed PI 3-ki-
nase activity associated with the PDGFR. Rat-1 cells were
treated with PDGF in the presence or absence of PE, and
cell extract proteins were immunoprecipitated with a PDGFRL
antibody. As expected, PI 3-kinase activity in the immunopre-
cipitates was greatly increased following treatment of cells
with PDGF, but no increase was detected after exposure to
PE alone (Fig. 1). The PDGF-induced activation of PI 3-ki-
nase was reduced by 43% in the presence of PE (Fig. 1).
3.2. PE inhibits tyrosine phosphorylation of the PDGFR and
binding to PI 3-kinase
One explanation for the result in Fig. 1 is that PE causes a
reduction in binding of PI 3-kinase to the activated PDGFR.
To test this possibility, we examined the association of the PI
3-kinase p85K regulatory subunit with the PDGFRL. The
amount of p85K that coimmunoprecipitated with the PDGFR
was markedly reduced in cells treated with PDGF plus PE, as
compared to cells treated with PDGF alone (Fig. 2A, top
blot). This result would be obtained if tyrosine phosphoryla-
tion of the PDGFR is reduced in the presence of PE. To test
this possibility, the blot was reprobed with an antibody to
phosphotyrosine. Tyrosine phosphorylation of the PDGFR
was lower in cells treated with PDGF plus PE than in cells
treated with PDGF alone (Fig. 2A, middle blot). The blot was
reprobed with PDGFRL antibody to show that similar
amounts of the receptor were present in each lane (Fig. 2A,
lowest blot). Similarly, the amount of p85K and tyrosine-
phosphorylated PDGFRL in anti-phosphotyrosine immuno-
precipitates was lower in cells treated with PDGF plus PE
than in cells treated with PDGF alone (Fig. 2B).
We next used a phosphospeci¢c antibody [6] to detect
changes in the phosphorylation state of the p85 binding site
at Tyr751 on the PDGFRL. Consistent with the previous
results, phosphorylation of Tyr751 increased in cells treated
with PDGF, and this response was reduced in the presence of
PE (Fig. 2C, upper blot). The blot was reprobed with PDGFRL
antibody to demonstrate equivalent loading of the protein in
each lane (Fig. 2C, lower blot). These results show that acti-
vation of the K1A adrenergic receptor antagonizes ligand-in-
duced phosphorylation of the PDGFR at Tyr751, resulting in
reduced binding of PI 3-kinase to the receptor.
3.3. Speci¢city of PE inhibition of PDGFR signaling
Ligand binding to the PDGFR promotes autophosphoryla-
tion of multiple tyrosine residues that recruit diverse signaling
molecules [7]. Attenuated PDGFR tyrosine phosphorylation
in the presence of PE could be due to a decrease in autokinase
activity of the PDGFR or to activation of PDGFR phospha-
tases. If PE treatment causes a decrease in autokinase activity,
then one might expect that other PDGF-activated signaling
pathways in addition to PI 3-kinase would be attenuated. It is
thought that PLCQ is recruited to and phosphorylated by the
PDGFR in response to PDGF stimulation [8]. To test if PE
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Fig. 1. E¡ect of PE on PDGFR-associated PI 3-kinase activity.
Cells were stimulated for 5 min with 25 ng/ml PDGF in the pres-
ence or absence of 10 WM PE. PI 3-kinase activity was measured in
PDGFRL immunoprecipitates. The experiment was repeated with
similar results.
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inhibits PDGF-induced tyrosine phosphorylation of PLCQ,
Rat-1 cells were treated with PDGF in the presence or ab-
sence of PE, and cell extract proteins were immunoprecipi-
tated with a PLCQ antibody. The immunoprecipitates were
then probed on a Western blot with antibody to phosphoty-
rosine. As expected, PDGF treatment stimulated the robust
tyrosine phosphorylation of PLCQ (Fig. 2D, upper blot).
However, cotreatment with PE did not reduce the level of
tyrosine phosphorylation of this protein. The blot was re-
probed with PLCQ antibody to show that similar amounts
of PLCQ were present in each lane (Fig. 2D, lower blot).
Similarly, phosphorylation of Tyr716 and Tyr771 on the
PDGFRL was not reduced in the presence of PE (Fig. 2E).
Finally, PDGFR kinase activity was measured in PDGFRL
immunoprecipitates. As expected, the PDGFR from cells
stimulated with PDGF had a markedly increased ability to
autophosphorylate in vitro as compared with the receptor
from untreated control cells (Fig. 2F). Treatment with PE
plus PDGF did not reduce PDGFR autophosphorylation.
These results indicate that stimulation of the K1A adrenergic
receptor does not inhibit all PDGFR-mediated responses, and
the e¡ect on phosphorylation of Tyr751 is probably not due
to a decrease in PDGFR kinase activity.
3.4. Activation of SHP-2 by PE plus PDGF
We next asked whether activation of a protein tyrosine
phosphatase could account for reduced phosphorylation of
the PDGFRL at Tyr751. SHP-2 is a ubiquitously expressed
Fig. 2. E¡ect of PE on binding of PI 3-kinase to the PDGFR. Cells were treated for 5 min with 50 ng/ml PDGF in the presence or absence of
10 WM PE. The results shown are representative of three independent experiments. PY: Phosphotyrosine; IP: immunoprecipitation. A: PDGFRL
immunoprecipitates were analyzed on a Western blot probed sequentially with antibodies to p85K (top blot), phosphotyrosine (middle blot),
and the PDGFRL (lowest blot). B: Phosphotyrosine immunoprecipitates were analyzed on a Western blot probed sequentially with antibodies
to p85K (upper blot) and phosphotyrosine (lower blot). C: Cell lysate proteins were analyzed on a Western blot probed sequentially with anti-
bodies to phospho-Tyr751 PDGFRL (upper blot) and total PDGFRL (lower blot). D: PLCQ immunoprecipitates were analyzed on a Western
blot probed sequentially with antibodies to phosphotyrosine (upper blot) and PLCQ (lower blot). E: Cell lysate proteins were analyzed on West-
ern blots probed with antibodies to phospho-Tyr716 PDGFRL (upper blot) and phospho-Tyr771 PDGFRL (bottom blot). F: PDGFRL immu-
noprecipitates were subjected to an autophosphorylation assay (see Section 2). 32P-labeled proteins were visualized by autoradiography. Num-
bers in kDa indicate the position of protein standards.
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protein tyrosine phosphatase that contains two SH2 domains.
SHP-2 binds to phospho-Tyr1009 on the activated PDGFRL
and may participate in the downregulation of receptor signal-
ing by dephosphorylating selective docking sites, including
phospho-Tyr751 and phospho-Tyr740 [9,10]. We measured
protein tyrosine phosphatase activity in SHP-2 immunopreci-
pitates after treating cells with growth factors alone or in
combination. Although there was a trend toward higher
SHP-2 phosphatase activity in response to either PDGF or
PE alone, the di¡erence as compared to untreated control
cells was not statistically signi¢cant (Fig. 3). However, after
treatment with both agents together there was a 60% increase
in activity that was highly statistically signi¢cant (Fig. 3). This
result suggests that activation of SHP-2 and subsequent de-
phosphorylation of Tyr751 on the PDGFRL could account at
least in part for the inhibitory e¡ect of the K1A adrenergic
receptor on PDGF-dependent PI 3-kinase signaling.
3.5. PMT inhibits PDGFR phosphorylation and signaling
to Akt
Stimulation of G protein-coupled receptors leads to GTP
loading of the heterotrimeric G protein K subunit and release
of the LQ subunits. The K and LQ proteins then exert their
e¡ects on downstream e¡ectors. Although the K1A adrenergic
receptor couples mainly to GK proteins in the q/11 family, the
receptor can also activate other types of GK subunits [11].
Since GLQ subunits activate PI 3-kinase [12,13], we decided
to explore a possible role for GKq in PI 3-kinase inhibition.
Treatment of cells with PMT induces a number of responses,
including activation of Rho, increased hydrolysis of phospho-
inositides, mobilization of intracellular Ca2þ, and activation of
protein kinase C. The latter three e¡ects appear to be due to
the activation of GKq [14,15]. Rat-1 cells were treated with or
without PMT prior to stimulation with PDGF, and the phos-
phorylation state of Tyr751 on the PDGFRL was analyzed.
The amount of phospho-Tyr751 was reduced in cells pre-
treated with PMT as compared with cells treated with
PDGF in the absence of the toxin (Fig. 4, top blot). The
inhibitory e¡ect of PMT on Tyr751 phosphorylation was
stronger than that seen using PE (Fig. 2C). To determine
the e¡ect of PMT on PI 3-kinase signaling, we examined the
phosphorylation state of Akt. Western analysis using a phos-
phospeci¢c antibody showed that PMT pretreatment partly
inhibited PDGF-induced Akt phosphorylation at Ser473
(Fig. 4, third blot). PMT treatment did not a¡ect the expres-
sion of the PDGFR or Akt (Fig. 4, second and bottom blots).
Together, these results suggest that activation of GKq, either
by agonists that bind to Gq-coupled receptors or by treatment
of cells with PMT, inhibits PDGF-dependent PI 3-kinase/Akt
signaling.
4. Discussion
Coordinate regulation of PI 3-kinase activity by receptor
tyrosine kinases and Gq-coupled receptors can substantially
alter cellular responses such as survival. Activation of PI 3-ki-
nase/Akt by receptor tyrosine kinases promotes cell survival
[16], whereas activation of GKq induces apoptosis in some cell
types [4]. Cardiac myocytes from transgenic mice that express
constitutively active GKq show an increased rate of apoptosis
[17], and Gq-coupled receptors are known to play an impor-
tant role in the development of heart failure [18]. Interference
with receptor tyrosine kinase activation of PI 3-kinase may
explain how Gq-coupled receptors promote cell death. We
have shown that PE treatment of Rat-1 cells expressing the
K1A adrenergic receptor augments UV-induced apoptosis and
inhibits activation of PI 3-kinase/Akt in response to PDGF,
insulin, and insulin-like growth factor I (IGF-I) [4,19]. This
study explores one mechanism underlying this inhibitory ef-
fect.
Our results show that activation of the K1A adrenergic re-
ceptor reduces PDGF-induced phosphorylation of the
PDGFR at Tyr751, thus eliminating a docking site for the
p85 subunit of PI 3-kinase. Decreased phosphorylation of
the PDGFR may be due to an increased rate of dephosphor-
ylation by SHP-2. It was reported that SHP-2 preferentially
dephosphorylates sites on the PDGFRL that are important
for PI 3-kinase binding, whereas the docking site for PLCQ
is a poor substrate [10]. Our ¢nding that PE inhibits PDGF
activation of PI 3-kinase but not PLCQ is consistent with those
results. SHP-2 has been reported to be activated by tyrosine
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Fig. 3. E¡ect of growth factors on SHP-2 activity. Cells were stimu-
lated for 5 min with 25 ng/ml PDGF in the presence or absence of
10 WM PE. Protein tyrosine phosphatase activity was measured in
SHP-2 immunoprecipitates (see Section 2). The data shown are
meansS standard error from four separate experiments. The asterisk
designates a signi¢cant di¡erence between Control and PE+PDGF
(P6 0.001) and between PDGF and PE+PDGF (P6 0.05). Pairwise
comparisons were made using Fisher’s post hoc tests.
PDGF -  +  -  + 
PMT
P-S473 Akt
Akt
P-Y751 PDGFR
PDGFR
Fig. 4. E¡ect of PMT on PDGFR signaling. Cells were treated for
18 h with or without 400 ng/ml PMT prior to stimulation for 5 min
with or without 25 ng/ml PDGF. Equal amounts of cell lysate pro-
tein were analyzed on Western blots probed sequentially with anti-
bodies to phospho-Tyr751 PDGFRL (top blot), total PDGFRL (sec-
ond blot), phospho-Ser473 Akt (third blot), and total Akt (bottom
blot). The experiment was repeated with similar results.
FEBS 27104 28-3-03
H.-Y. Lin et al./FEBS Letters 540 (2003) 106^110 109
phosphorylation [20] or by binding of phosphotyrosyl pep-
tides to its SH2 domains [21], whereas serine/threonine phos-
phorylation [22] and reactive oxygen species [23] have been
reported to inhibit the enzyme. We currently do not know if
any of these mechanisms contribute to SHP-2 activation in
cells treated with PDGF plus PE.
Some other Gq-coupled receptors have been shown to an-
tagonize growth factor activation of PI 3-kinase by reducing
tyrosine phosphorylation. For example, pretreatment of rat
aortic smooth muscle cells with angiotensin II inhibited insu-
lin-stimulated tyrosine phosphorylation of insulin receptor
substrate-1 (IRS-1), resulting in decreased PI 3-kinase activa-
tion [24]. It was hypothesized that either (a) increased serine
phosphorylation of IRS-1 in the presence of angiotensin II
prevents the protein from docking to and being phosphory-
lated by the activated insulin receptor, thus preventing IRS-1
from binding and activating PI 3-kinase, or (b) angiotensin II
induces the rapid dephosphorylation of IRS-1 via the activa-
tion of a protein tyrosine phosphatase. We speculate that
protein tyrosine dephosphorylation might be a general mech-
anism used by Gq-coupled receptors to oppose the activation
of PI 3-kinase by a variety of growth factors.
Although PMT exerts pleiotropic e¡ects on cells, recent
studies in ¢broblasts lacking GKq or the closely related GK11
showed that production of inositol phosphates in response to
toxin treatment is dependent on GKq (not GK11) [15]. We used
PMT to investigate how receptor-independent activation of
GKq a¡ects PDGF signaling, and found that the toxin mimics
the e¡ect of PE by inhibiting PDGFRL phosphorylation and
Akt activation. PMT has also been shown to inhibit Akt
phosphorylation promoted by epidermal growth factor or
IGF-I treatment of neonatal rat cardiac myocytes [25]. Based
on these results, we hypothesize that activated GKq mediates
PI 3-kinase inhibition. This hypothesis is supported by the
observation that expression of an activated mutant of GKq
opposes growth factor activation of PI 3-kinase (L.M. Ballou,
H.-Y. Lin, G. Fan, Y.-P. Jiang and R.Z. Lin, submitted
manuscript).
In conclusion, our results demonstrate that one mechanism
used by the K1A adrenergic receptor to antagonize PDGF
activation of PI 3-kinase involves dephosphorylation of the
PDGFR. Further study of the cross-talk between these two
classes of receptors might reveal important insights into dis-
eases such as heart failure and diabetes.
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